Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 12/20 | 0.66 |
| ▸ | PDE9A | O76083 | 3/20 | 0.48 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6699447 | 0.83 | KCNMA1 (0.88) | KCNMA1PDE9AGRM4KDM4E | |
| SCHEMBL31261456 | 0.81 | KCNMA1 (0.68) | KCNMA1PDE9APARP1 | |
| SCHEMBL30052094 | 0.79 | KCNMA1 (0.66) | KCNMA1PDE9APARP1 | |
| SCHEMBL6702066 | 0.79 | KCNMA1 (1.00) | KCNMA1PDE9APARP1KDM4ECYP1A2 | |
| SCHEMBL23885624 | 0.79 | KCNMA1 (0.66) | KCNMA1PDE9APARP1 | |
| SCHEMBL4754780 | 0.78 | PDE9A (0.60) | KCNMA1PDE9APARP1KDM4E | |
| SCHEMBL6686120 | 0.77 | KCNMA1 (1.00) | KCNMA1PDE9APARP1 | |
| SCHEMBL6687702 | 0.76 | KCNMA1 (0.77) | KCNMA1PDE9APARP1 | |
| SCHEMBL6683225 | 0.75 | KCNMA1 (1.00) | KCNMA1PDE9AKDM4E | |
| SCHEMBL6687522 | 0.74 | KCNMA1 (1.00) | KCNMA1PDE9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016029146-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON (US) | 2016-02-25 | — | — | WO | claimed |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | UNIVERSITY OF WASHINGTON (US) | 2021-02-09 | — | — | US | disclosed |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | UNIVERSITY OF WASHINGTON (US) | 2021-02-09 | — | — | US | disclosed |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON | 2017-09-28 | — | — | US | disclosed |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON | 2017-09-28 | — | — | US | disclosed |
| US-20040192697-A1 | Pyrrolopyridine potassium channel openers | ABBOTT LABORATORIES | 2004-09-30 | — | — | US | disclosed |
| WO-2004060893-A1 | PYRROLOPYRIDINE POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040122218-A1 | Pyrrolopyridine potassium channel openers | ABBOTT LABORATORIES | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122218-A1 | Pyrrolopyridine potassium channel openers | KCNJ2, KCNN1, KCNN2 | KCNMA1 12/4885PDE9A 1831/4885PSMB8 3760/4885 |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | AARS1, MTR, GARS1 | KCNMA1 4736/4885PDE9A 3467/4885PSMB8 3624/4885 |
| US-20040192697-A1 | Pyrrolopyridine potassium channel openers | KCNJ2, KCNN1, KCNN2 | KCNMA1 12/4885PDE9A 1831/4885PSMB8 3760/4885 |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | AARS1, MTR, GARS1 | KCNMA1 4736/4885PDE9A 3467/4885PSMB8 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.